Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders

被引：109
作者：
Hahn M.K. [1 ]
Blakely R.D. [1 ]
机构：
[1] Vanderbilt University, Department of Pharmacology, Center for Molecular Neuroscience, Nashville, TN 37232-6420
来源：
The Pharmacogenomics Journal | 2002年 / 2卷 / 4期
关键词：
Dopamine; Norepinephrine; Polymorphism; Serotonin; SNP; Transporter;
D O I：
10.1038/sj.tpj.6500106
中图分类号：
学科分类号：
摘要：
The norepinephrine, dopamine and serotonin transporters (NET, DAT and SERT, respectively), limit cellular signaling by recapturing released neurotransmitter, and serve as targets for antidepressants and drugs of abuse, emphasizing the integral role these molecules play in neurotransmission and pathology. This has compelled researchers to search for polymorphisms in monoamine (MA) transporter genes. Studies support linkage and association of MA transporter genetic variation in psychiatric and other complex disorders. Understanding the contribution of MA transporter polymorphisms to human behavior, disease susceptibility and response to pharmacotherapies will involve further progress in linkage and association that will be aided by both definition of highly selective phenotypes and utilization of a large number of polymorphic markers. The relationship of polymorphisms to alterations in transport capacity, likely a complex interaction, involving genetic background, disease state, and medication, will elucidate the means by which MA transporter genetic variability contributes to our individuality.
引用
收藏
页码：217 / 235
页数：18
相关论文
共 155 条
  • [1] Schildkraut J.J., The catecholamine hypothesis of affective disorders: A review of supporting evidence, Am. J. Psychiatry, 122, pp. 509-522, (1965)
  • [2] Ressler K.J., Nemeroff C.B., Role of norepinephrine in the pathophysiology and treatment of mood disorders, Biol. Psychiatry, 46, pp. 1219-1233, (1999)
  • [3] Leonard B.E., The role of noradrenaline in depression: A review, J. Psychopharmacol, 11, (1997)
  • [4] Klimek V., Stockmeier C., Overholser J., Meltzer H.Y., Kalka S., Dilley G., Ordway G.A., Reduced levels of norepinephrine transporters in the locus coeruleus in major depression, J. Neurosci, 17, pp. 8451-8458, (1997)
  • [5] Bohm M., La Rosee K., Schwinger R.H., Erdmann E., Evidence for reduction of norepinephrine uptake sites in the failing human heart, J. Am. Coll. Cardiol, 25, pp. 146-153, (1995)
  • [6] Liang C.S., Fan T.H., Sullebarger J.T., Sakamoto S., Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamber-specific contributor to beta-adrenoceptor downregulation, J. Clin. Invest, 84, pp. 1267-1275, (1989)
  • [7] Merlet P., Dubois-Rande J.L., Adnot S., Bourguignon M.H., Benvenuti C., Loisance D., Et al., Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy, J. Cardiovasc. Pharmacol, 19, pp. 10-16, (1992)
  • [8] Schafers M., Dutka D., Rhodes C.G., Lammertsma A.A., Hermansen F., Schober O., Camici P.G., Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy, Circ. Res, 82, pp. 57-62, (1998)
  • [9] Esler M., Jackman G., Bobik A., Leonard P., Kelleher D., Skews H., Et al., Norepinephrine kinetics in essential hypertension. Defective neuronal uptake of norepinephrine in some patients, Hypertension, 3, pp. 149-156, (1981)
  • [10] Imamura M., Lander H.M., Levi R., Activation of histamine H3-receptors inhibits carrier-mediated norepinephrine release during protracted myocardial ischemia. Comparison with adenosine A1 -receptors and alpha2-adrenoceptors, Circ. Res, 78, pp. 475-481, (1996)
12345678910